8-K filing — PULSE BIOSCIENCES, INC. (PLSE)
Filed: 2026-10-14 AccNo: 0001437749-26-032601 Size: 171 KB Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Pulse Biosciences Announces Completion Of 164-Patient Enrollment In Pivotal Atrial Fibrillation Study Of nPulse Catheter, Three Months Ahead Of Schedule
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Pulse Biosciences Partners With Clayman Thyroid Center At Hospital For Endocrine Surgery In Tampa, Florida
Collaboration adds the nPulse™ Vybrance™ System to patient care at the Hospital for Endocrine Surgery and supports generation of additional clinical dataPulse Biosciences, Inc. (NASDAQ:PLSE), the company leveraging its
Oppenheimer Maintains Outperform on Pulse Biosciences, Raises Price Target to $60
Oppenheimer analyst Suraj Kalia maintains Pulse Biosciences (NASDAQ:PLSE) with a Outperform and raises the price target from $35 to $60.